Insmed Incorporated

INSM

$39.8

+73.47% (1 year change)

Avg closing price

Price range

Market Cap

$4.05 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$42.5 Million

Total revenue in the last quarter.

Net Income

$-61.9 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$-2.6

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

-

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-15.32x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$-54.1 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

435

The number of full time employees.

Revenue & Earnings

Balance Sheet

Insmed Incorporated

Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

News

Insmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference

Insmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference

BRIDGEWATER, N.J., Nov. 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare disease...

PR Newswire PR Newswire, 6 days ago
Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)

Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)

BRIDGEWATER, N.J., Nov. 13, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare disease...

PR Newswire PR Newswire, 17 days ago
LAMIRA®, an eFlow® Technology nebuliser, is the first and only device to deliver Insmed's ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion in the European Union

LAMIRA®, an eFlow® Technology nebuliser, is the first and only device to deliver Insmed's ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion in the European Union

STARNBERG, Germany, Nov. 2, 2020 /PRNewswire/ -- PARI Pharma GmbH, a company focused on the development, manufacturing and commercialisation of advanced aerosol delivery systems based on eFlow Tech...

PR Newswire PR Newswire, 27 days ago